Endoscopic Full Thickness Resection Versus Standard Therapy of the Colorectal Neoplasia


Military University Hospital, Prague




Colon Cancer


Device: EMR and ESD
Device: Over- the- scope full- thickness resection device

Study type


Funder types




Details and patient eligibility


Most of the cancers develop from the adenomatous polyps. The therapeutic methods have been established already - endoscopic polypectomy (EPE) for stalked polyps and endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for non-pedunculated polyps. EMR is preferred in European countries over ESD because of its higher feasibility. However, the local residual neoplasia (LRN) after EMR has been reported in 14 - 24 % cases. There is a higher LRN risk in sessile polyps which do not elevate sufficiently after the submucosal injection (non-lifting sign) and the piece-meal resection needs to be used. Therefore, the new method of endoscopic full-thickness resection (FTR) has been developed to resect these lesions.

Full description

In this project, 80 individuals (age ≥ 18 years) with colorectal lesions of 10-25 mm size with positive non-lifting sign will be included. Such lesions might be found during the colonoscopies at the trial endoscopy centers or at the cooperating referring endoscopy centers outside the study. Patient will be scheduled for the index therapeutic colonoscopy (iTC) and randomized in two groups - FTR group (therapy with FTRD) and ST group (standard therapy, EMR or ESD due to the indication, decided by the endoscopist). First follow-up colonoscopy (FC1) will be performed in 6 months interval. In case of LRN negativity at FC1, the second follow-up colonoscopy (FC2) will be done after 12 months (18 months since iTC). In case of LRN positivity at FC1, the LRN therapeutic colonoscopy (LRN-TC) will follow with the endoscopic method due the findings (patients will be divided into four groups): APC group (LRN ≤ 5 mm; APC therapy), EMR group (LRN > 5 mm and negative non-lifting sign negative; EMR therapy), FTR group (LRN > 5 mm and positive non-lifting sign; therapy with FTRD) and surgery group (complex lesion; surgical therapy). In some LRN positive cases, FC1 will be the same as LRN-TC. The first follow-up colonoscopy after LRN therapy (LRN-FC1) will be performed after 6 months (12 months since TC). In case of re-LRN negativity at LRN-FC1 the second follow-up colonoscopy after LRN therapy (LRN-FC2) will be done after 6 months (18 months since iTC). In case of re-LRN positivity at LRN- FC1 the therapy will be done same as during FC1 and next follow-up will be done outside this trial. In some re-LRN positive cases, LRN-FC1 will be the same as re-LRN-TC. In conclusion, all patients will be followed-up within the study for 18 months, if timely possible.


80 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • age ≥ 18 years
  • colorectal lesions of 10-25 mm size with positive non-lifting sign
  • signed informed consent with the study and with colonoscopy

Exclusion criteria

  • age < 18 years
  • lesions > 25 mm
  • pedunculated polyps
  • colorectal stenosis
  • colonoscopy contraindication
  • severe acute inflammatory bowel disease
  • severe comorbidities
  • patient not able to sign the informed consent

Trial design

80 participants in 2 patient groups

Experimental group
Standard EMR or ESD technique
Device: EMR and ESD
Over- the- scope full- thickness resection device
Experimental group
Endoscopic full thickness resection
Device: Over- the- scope full- thickness resection device

Trial contacts and locations



Central trial contact

Michal Voska, MD.; Stepan Suchanek, MD., Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems